Lava fountains over 1,000 feet high shoot from Hawaii's Kilauea volcano
Hawaii's Kilauea volcano sent jets of lava shooting over 1,000 feet into the air early Friday morning, marking another explosive episode for the active volcano.
The volcanic activity began at 11:30 p.m. local time Thursday, according to the Hawaiian Volcano Observatory, which is operated by the U.S. Geological Survey. At first, the activity was "small, sporadic spattering" and lava outflows, the observatory said. But as time went on, the activity "continued to increase in intensity."
By 1:40 a.m. Friday, the lava fountains erupting from the volcano's north vent were reaching heights of over 1,000 feet, the observatory said. That intensity overlapped with an increase in seismic activity, the observatory said.
Fifteen minutes later, at 1:55 a.m. local time, the volcano was continuing to emit 800-foot-high fountains of lava. A camera at the volcano continued to livestream images of impressive lava fountains shooting into the air.
Lava erupts from Kilauea on June 20, 2025.
U.S. Geological Survey
The fountains are feeding a lava flow, the observatory said. The lava flow remains contained in the Halema'uma'u caldera, a crater at the top of the volcano, the observatory said.
The volcano also released a volcanic cloud about 15,000 feet into the air. The observatory warned that the plume may include hazards, including strands of volcanic glass known as Pele's hair and rock fragments called tephra. These hazards, along with volcanic gas, can have "far-reaching effects downwind," the observatory said. Winds around the volcano are blowing from the north, so these fragments may be distributed south of the caldera, the observatory said.
This is the volcano's 26th lava fountaining episode since December 2024. Most episodes have lasted for a day or less, and are separated by pauses of at least several days, the observatory said.
Kilauea, located on the Big Island's Hawaii Volcanoes National Park about 200 miles from Honolulu, is one of six active volcanoes in Hawaii. It is also one of the world's most active volcanoes. Its eruptions have become a popular attraction. The USGS also offers multiple YouTube livestreams of the volcanic activity.
Hawaii is also home to the largest active volcano in the world, Mauna Loa. The volcano is also located in Hawaii Volcanoes National Park and last erupted in 2022.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
If Your Baby Seems Kinda Dumb at Seven Months, Scientists Have Terrible News About What'll Happen When It Grows Into an Adult
Next time you see your baby trying to play or talk, pay close attention — because it may give you a strong clue about how intelligent the kiddo will turn out as an adult, according to a new paper in the journal PNAS. A team of scientists led by the University of Colorado Boulder have found that cognitive tests on babies as young as seven months can anticipate their future performance as 30-year-old adults on intelligence tests. "We certainly do not want to imply that cognition is somehow fixed by seven months old," said first author Daniel Gustavson, an assistant research professor at the university's Institute for Behavioral Genetics, in a statement. "But the idea that a very simple test in infancy can help predict the results of a very complicated cognitive test taken 30 years later is exciting." But all isn't lost if your baby seems slow on the uptake right now: the scientists also determined that environmental factors have an impact on childhood development. The researchers examined data from the Colorado Longitudinal Twin Study, which was started in 1985 and involved more than 1,000 twins who were followed since they were babies in order to study the impact of genes and environment. Previous research has already found that general cognitive ability doesn't shift much after a kid is eight years old or so, but this team wanted to investigate if this was also true starting from when children are very young. The researchers looked at several metrics to assess cognitive ability in babies, such as the focus and vocalization found in baby babbles. From these yardsticks, they determined that two metrics — object novelty and task orientation — strongly predicted the cognitive abilities of the tykes once they hit adulthood. They also compared identical and fraternal twins, from which they determined that 22 percent of the variance in adult cognitive ability was connected with genetic influences present in children three years of age or younger. However, they also found out that environmental influences when a child was one or two years old could explain 10 percent of variability in adult cognitive tests. Perhaps this finding will dispel the notion that genes have a total monopoly on intelligence, especially in light of right wing activists recently glomming onto race science and IQ. After all, the human brain is complex; if you feel dumb, maybe you just haven't found the right type of task yet. More on babies: The World Birth Rate Is Now Dropping Precipitously
Bloomberg
3 hours ago
- Bloomberg
Senate Can Keep Ban on State AI Rules in Trump Tax Bill
A Republican effort to block US states from enforcing new artificial intelligence regulations will remain in President Donald Trump's massive tax and spending package for now, marking a win for tech companies pushing to stall and override dozens of AI safety laws across the country. In a surprise decision, Democrats said the Senate parliamentarian ruled the provision aligns with the special budgetary process Republicans are using to consider the tax package. That process allows the GOP to avoid making concessions to Democrats, who otherwise could filibuster legislation.
Yahoo
3 hours ago
- Yahoo
Parkinson's Discovery Suggests We Could Have an FDA-Approved Treatment Already
Researchers have discovered how a surface protein on brain cells, called Aplp1, can play a role in spreading material responsible for Parkinson's disease from cell to cell in the brain. Promisingly, an FDA-approved cancer drug that targets another protein – Lag3 – which interacts with Aplp1 – was found to block this process in mice. This suggests a potential treatment for Parkinson's may already exist. In a paper published last year, an international team of scientists detailed how the two proteins work together to help toxic clumps of alpha-synuclein protein get into brain cells. "Now that we know how Aplp1 and Lag3 interact, we have a new way of understanding how alpha-synuclein contributes to the disease progression of Parkinson's disease," neuroscientist Xiaobo Mao from Johns Hopkins University said in June 2024. "Our findings also suggest that targeting this interaction with drugs could significantly slow the progression of Parkinson's disease and other neurodegenerative diseases." More than 8.5 million people globally have Parkinson's, the second most common neurodegenerative disease after Alzheimer's. The disease is progressive and currently incurable, and it's usually only diagnosed when symptoms show. These include tremors, stiffness, balance issues, speech difficulties, disturbed sleep patterns, and mental health issues. In advanced stages, patients may eventually struggle to walk or speak. Most Parkinson's symptoms stem from the loss or dysfunction of dopamine-producing neurons in a brain region involved in fine motor control, called the substantia nigra. This is thought to be caused by Lewy bodies – abnormal clumps of protein, primarily made up of misfolded alpha-synuclein, that move from neuron to neuron. Although alpha-synuclein normally helps neurons communicate, when it misfolds and becomes insoluble, it can cause serious damage. That said, identifying whether this is a cause of Parkinson's or a symptom is difficult. Past studies on mice found Lag3 binds to alpha-synuclein proteins and spreads Parkinson's disease pathology in neurons. While deleting Lag3 significantly impedes this process, it does not completely prevent it, indicating another protein was also implicated in neurons taking in misfolded alpha-synuclein. "Our work previously demonstrated that Lag3 wasn't the only cell surface protein that helped neurons absorb alpha-synuclein, so we turned to Aplp1 in our most recent experiments," said Johns Hopkins neuroscientist Valina Dawson. The scientists conducted tests with genetically modified mice that were missing either Aplp1 or Lag3, or both. They found Aplp1 and Lag3 can each independently help brain cells absorb harmful alpha-synuclein, but together they significantly increase the uptake. When mice were missing both Aplp1 and Lag3, 90 percent less of the harmful alpha-synuclein entered healthy brain cells, meaning a greater amount of the harmful protein clumps was blocked with both proteins missing compared with a deletion of just one. The researchers gave normal mice the drug nivolumab/relatlimab, a melanoma medication that contains a Lag3 antibody, and found that it also stopped Aplp1 and Lag3 from interacting, again almost completely blocking the formation of disease-causing alpha-synuclein clumps in neurons. "The anti-Lag3 antibody was successful in preventing further spread of alpha-synuclein seeds in the mouse models and exhibited better efficacy than Lag3-depletion because of Aplp1's close association with Lag3," said Ted Dawson, a neuroscientist at Johns Hopkins University. The next step will be to test the Lag3 antibody on mouse models of Parkinson's disease and Alzheimer's – where research has pointed to Lag3 as a target too. The research has been published in Nature Communications. An earlier version of this article was published in June 2024. Microplastics Have a Concerning Effect on The Microbes in Our Gut Something in Your Poop May Predict an Imminent Death Long-Term Contraceptive Pill Use Linked With Brain Tumor Risk
